Affiliation
University of Manchester; The Christie National Health Service Foundation Trust, Manchester, United KingdomIssue Date
2015-06-29
Metadata
Show full item recordCitation
To BRCA or Not to PALB. 2015: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2014.60.0585PubMed ID
26124473Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2014.60.0585
Scopus Count
Collections
Related articles
- The long and winding road.
- Authors: DenBrok W, Simmons C, Gelmon KA
- Issue date: 2015 Jan 20
- Reply to M.G. McNamara et al and M.S. Copur et al.
- Authors: Domchek SM, Kaufman B, Friedlander M
- Issue date: 2015 Aug 10
- Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
- Authors: Copur MS, Gauchan D, Brussow K, Clark D, Ramaekers R
- Issue date: 2015 Aug 10
- Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
- Authors: Venkitaraman AR
- Issue date: 2009 Aug 4
- Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
- Authors: Altundag K
- Issue date: 2021 Sep-Oct